Institute Of Mother And Child, Warsaw, Poland

This study tests a drug called regorafenib in people aged 9 to 21 with bone cancer (osteosarcoma or Ewing sarcoma) that has come back or not responded to standard therapy. The goal is to see if the drug can help control the cancer and to find the right dose. Researchers will also…